Using Philadelphia chromosome-positive (Ph') chronic myelogenous leukemia (CML) as a model, our aim has been t o develop a molecular cytogenetic method of high resolution analysis for monitoring the frequency of cells with nonrandom chromosome rearrangements in the bone marrow of patients receiving treatment for hematologic malignancies. Long-term exposure (24 hours) of bone marrow cultures t o colcemid (0.1 pg/mL) maximized a high frequency of metaphase collection. Such preparations were subjected t o fluorescence in situ hybridization (FISH) using a 5 Mb probe that overlapped the region of the translocation at chromosome 9q34. This detected the Ph translocation in the resultant large number of overly contracted chromosome spreads. The procedure was validated and verified by studying 70 double-blind marrow samples from patients in different stages of Ph' CML and from patients with Ph-hematologic malignancies (controls). This hypermetaphase FISH (HMF) method clearly identified Ph' metaphases and allowed IEMSA-BAND chromosome analysis (CG) has been the standard for determination of the presence of the Philadelphia chromosome (Ph) in the bone marrow of patients with chronic myelogenous leukemia (CML).' While extremely reliable when a good harvest of metaphases is obtained from a marrow culture, more than 20 to 25 metaphases are rarely recovered from patients in therapy. Consequently, in patients with CML receiving treatment, monitoring the effect of therapy by CG is limited with respect to detecting minimal residual disease ( M m ) and identifying significant changes in Ph+ cell frequency. Analyzing greater numbers of metaphases per sample would provide higher resolution and greater efficiency in addressing those issues.
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IEMSA-BAND chromosome analysis (CG) has been
the standard for determination of the presence of the Philadelphia chromosome (Ph) in the bone marrow of patients with chronic myelogenous leukemia (CML).' While extremely reliable when a good harvest of metaphases is obtained from a marrow culture, more than 20 to 25 metaphases are rarely recovered from patients in therapy. Consequently, in patients with CML receiving treatment, monitoring the effect of therapy by CG is limited with respect to detecting minimal residual disease ( M m ) and identifying significant changes in Ph+ cell frequency. Analyzing greater numbers of metaphases per sample would provide higher resolution and greater efficiency in addressing those issues.
If a significant proportion of the cells cycling in the marrow could be arrested at the metaphase stage, hundreds, or even thousands, could be collected onto a slide for analysis. Short-term treatment (30 to 60 minutes) of cultures with a mitotic arresting agent, colcemid, is the procedure presently used to provide metaphases for analysis.* It has been optimized to collect metaphases in which the chromosomes are sufficiently elongated and separated for G-band analysis. Unfortunately, longer colcemid treatment, for greater numbers of collected metaphases, results in chromosomes becoming overly contracted, with a general deterioration in morphology and distribution. Such preparations are inappropriate for CG analysis, which requires well-spread metaphases in which the chromosomes retain good morphology.
We have shown that using a probe that will detect the Ph translocation by fluorescence in situ hybridization (FISH), a clear, rapid, and unambiguous signal detected Ph' cells in metaphases that would, in general, be considered unacceptable for CG a n a l~s i s .~.~ Here, we have conducted experiments to maximize the frequency of cells arrested in metaphase (hypermetaphases). By performing FISH on these preparations, in a procedure we will refer to as hypemetaphase/FTSH (HMF), we expected that high resolution enuBlood, Vol 86, No 6 (September 15), 1995: pp 2343-2349 G the analysis of 500 hypermetaphases per sample in less than 1 hour after FISH. HMF (1) identified statistically significant differences between the frequencies of Ph' cells in samples that differed by less than 4%; (2) resolved such differences among patient samples that were all judged 100% Ph' by standard G-band cytogenetics (CGI; (3) resulted in the reclassification of response status in 23% of the patients initially classified by CG; (4) recognized Ph' cells in 16% of patients characterized as having a complete cytogenetic response and in one patient with an original diagnosis of Ph-CML; and (5) was informative where insufficient metaphases were obtainable for analysis by CG. HMF appears t o be uniquely suitable for monitoring the status of patients with CML receiving treatment. It should also be applicable for patients with any hematologic diseases where chromosomal alterations are known and appropriate FISH probes are available. meration and analysis of Ph+ cells in marrow preparations would be available to monitor MRD and to observe subtle alterations of the frequency of Ph' cells in patients in various stages of therapy. In this study, we report the results of experiments to determine the effectiveness of HMF. Blinded marrow samples from a large series of patients with CML in different stages of disease and treatment as well as from control patients were studied. We report the power of the procedure to detect MRD and to identify statistically significant alterations in the frequency of Ph+ cells in response to therapy.
MATERIALS AND METHODS
Hypermetaphuse studies. Bone marrow cells from five normal individuals (prospective donors for allogeneic bone marrow transplantation) and seven patients with CML were studied to optimize conditions for hypermetaphase preparations. All patient samples in this report were obtained as part of a program sponsored by the National Cancer Institute, and appropriate informed consent was obtained from all patients. Cells were cultured in T25 tissue culture 2344 SEONG ET AL flasks containing 10 mL of RPMI 1640 medium (GIBCO, Gaithersburg, MD) with 10% serum (GIBCO; newborn bovine serum: fetal bovine serum, 1 : 1). Cell densities were adjusted to not exceed 5 X 106/mL, and incubation at 37°C with 5% CO, for 24 hours was conducted. Cultures were then subdivided and exposed to varying concentrations (0.01 to 0.4 pglmL) of colcemid (N-methyl N deacetyl-colchicine in phosphate-buffered saline [PBS]; Boehringer Mannheim) over varying time periods (0.5 to 48 hours). Efficiency of each procedure in collecting metaphases was determined by calculating the mitotic index (total number of mitotic figures seen on a slide onto which a fixed preparation had been dropped per 1,000 for the total number of cells counted) for the preparation. Conditions providing the highest mitotic indices were the conditions applied to the coded samples.
Study population. From March 1993 through May 1994, 70 patients with hematologic malignancies were included in this investigation after informed consent was obtained according to institutional guidelines. Bone marrow aspirations were obtained by four investigators (H.M.K., M.T., R.E.C. and J.R.R.), coded, and sent as blinded, coded samples for both CG (to the Clinical Cytogenetics Laboratory, University of Texas M.D. Anderson Cancer Center) and HMF (to D.C.S., J.X., and M.J.S.). HMF preparations were made by J.X. All HMF slides were read by D.C.S. Those making the HMF preparations had no knowledge of the patient's identity, diagnosis, or cytologic response status for any of the samples studied. After all the data were tabulated, the code was broken, and it was then determined what the correlations were between the HMF results and the type of patient sample analyzed.
Fifty-eight patients with Ph+ CML in various states of responsiveness to therapy as well as one patient with a diagnosis of Phnegative CML were entered into the study. An additional 11 patients were recruited that had other hematologic malignancies: acute lymphocytic leukemia (ALL), acute myelogenous leukemia (AML), and chronic lymphocytic leukemia (CLL). This latter group comprised the presumed Ph-controls. The acute leukemia patients were in first remission, while the CLL patients had active disease. The number of patients in each group and the status of the cytogenetic response of patients with Ph+ CML are listed in Table 1 .
G-band cytogenetic analysis (CC). Cytogenetic analysis was
performed on freshly aspirated bone marrow samples. Metaphases were analyzed for G-bands using trypsin-Giemsa techniques as previously described.* Consistent with the routine analysis, 20 to 25 metaphases were analyzed. Cytogenetic response was defined relative to the percentage of Ph+ cells identified by CG: complete if 0%, partial if from 1% to 34%, minor if from 35% to 95%, and none if greater than 95% Ph cells? Slide preparation. Marrow cells were transferred from culture flasks to 15-mL Falcon tubes and then spun at 1,200 rpm for 5 minutes. Ten milliliters of hypotonic KC1 (0.075 mow) was added to the pellet for 20 minutes at 37°C. Then, 1 mL of fixative solution (methano1:acetic acid, 3:l) was added, and cells were spun down for 5 minutes at 1,200 rpm. Supernatant was decanted and the pellet was resuspended in fixative for at least 20 minutes at room temperature and spun as above. This process was repeated two to three times until the pellet was white. Cells were then left in 2 mL fixative.
FISH. Probe for FISH was prepared from radiation hybrid E6B, which has been shown to contain only approximately 5 Mb of human DNA from human chromosome band 9q34 as its only human genomic content. Molecular marker analysis has indicated that the human region retained extends from A K l to ABO, which includes ABL, and that approximately one third of the region is translocated to the Ph chromosome in patients with CML.6 The probe, therefore, allows the ready detection of three signals (from the normal chromosome 9, the chromosome 9q+, and the Ph chromosome), while only two signals from the chromosomes 9 are seen in normal metaphases! Methods for preparation of human specific FISH probe from hybrid cells by inter-Ah-polymerase chain reaction (PCR), biotin-labeling of probe, competitive hybridization blocking of repeat sequences, FISH, avidin-fluorescein detection, ultraviolet microscopy, and photography as performed in this laboratory have been described by Liu et E6B probe was visualized in cells as yellow-green fluorescence when viewed through a B2A Nikon filter (excitation, 470 to 490; emission, 515; Nikon Inc, Melville, NY). Photomicrographs were taken on Kodak 160 Ectachrome (Eastman Kodak, Rochester, NY) directly without image enhancement or processing.
RESULTS
After 24 hours of culture in RPMI medium and 10% fetal calf serum, bone marrow cultures were exposed to varying concentrations of colcemid (0.01 to 0.4 pg/mL) over varying time periods (0.5 to 48 hours). Maximum metaphase collection was achieved after 24 hours of culture in 0.1 pg/mL. This resulted in a 3% to 6% mitotic index in preparations from normal marrows, and 4% to 15% from patients with CML (with higher levels observed in samples with higher percentages of Ph+ cells). As shown in Fig 1, multiple metaphase figures were present in a single microscope field. The chromosomes in most such figures were highly overcontracted and useless for a karyotype analysis. However, when E6B FISH probe was applied to such metaphases from a CML marrow culture, Ph+ cells could be readily distinguished from cells not carrying the Ph translocation (Fig 2) .
The presence of only two pairs of FISH signals, as shown in Fig 2A, is interpreted as being typical of a non-Ph+ cell throughout this procedure. As the E6B probe marks the terminal portion of the q-arm of chromosome 9, and as in overly contracted chromosomes (a consequence of the 24 hours in colcemid) chromatids of a chromosome tend to fly apart while being held together at their centromeres, each chromosome is seen as a pair of signals, with each signal of the pair representing a chromatid. Figure 2B moved from the 9q-chromosome to the Ph chromosome.6 less ideal yet still interpretable cells were identified and clasRarely, the paired signals became completely separated, re-sified. In the cell at the top of Fig 2C, the two chromosomes sulting in four signals of relatively equal intensity (interpre-9 are crowded together, and the paired signal is resolved on ted as a normal cell) or six signals (two with lesser intensity; only one of them, while the cell on top in Fig 2D exhibits interpreted as a Ph+ cell). In addition to these ideal situations, a metaphase of very poor quality in which the two signals For of one of the pairs (on the right) appears stretched apart. These cells were scored as not being Ph', because the third paired signal regions were not observed. In the cell at the bottom of Fig 2D, the signal from the Ph chromosome does not appeared paired. This was a frequent observation, as that signal is closer to the centromere than the signal at the end of the 9q chromosome, and, therefore, the chromatids often are not sufficiently separated to resolve the signal as paired. However, such cells were scored as Ph', as the unpaired signal was clearly in addition to clear signals from the chromosomes 9 and 9q-. The following rare types of cells were not counted: cells poorly stained because of being under a bubble or in an area of the slide with poor staining and cells in which the nucleus was clearly not intact. These represent the spectrum of types of signals in cells and how they were interpreted in the analysis of patient samples. Scoring 500 or more such cells per sample for presence or absence of the Ph chromosome by the criteria indicated could be performed in less than 1 hour. To determine the quantitative limits of this procedure in detecting the frequency of Ph+ cells in a heterogeneous population, doubleblind experiments were conducted as described in Materials and Methods on samples from patients with CML in different clinical states of disease and control samples from putative non-Ph' patients. The results are reported in Tables 2  through 4 and are described below.
Control population. In 10 of the l 1 blinded control samples, no Ph' cells were detected by HMF out of at least 500 metaphases analyzed per sample. All 10 had a diploid karyotype as determined by CG. One of the blind samples provided as a control, D052 (Table Z) , turned out to be a Ph' ALL. We scored 505 cells and determined that 76.2% were Ph+. When notified of our result, co-investigators who randomly inserted control samples among the CML samples and who had access to the CG results verified that CG on patient D052 conducted at the same time indicated 15 of 20 cells (75%) to be Ph+. These data clearly verify the effectiveness of the probe on these preparations to specifically identify the presence of the Ph chromosome in such samples. Applying a Clopper-Pearson confidence interval for a binomial proportion,' we conclude that getting no false-positive readings in 500 cells of a blinded control sample allows US to have 99% confidence that when no Ph + cells are identified in a 500-cell sample, the maximum frequency of Phi-cells present in the sample is less than 1%.
HMF and CG results in patients with CML. Samples of 16 patients classified as having no cytogenetic response (Table 3) and determined to be 100% Ph' by CC had from 91.0% to 99.0% Ph' cells by HMF. In no case was the frequency of Ph' cells determined by HMF statistically significantly different from the frequency determined by CG. In the case with the greatest difference (D372), 20 of 20 Ph' cells by CG compared with 455 of 500 by HMF produced x' of only 1 .0 ( P < .32). The lack of a statistically significant difference is attributable to the small number of cells studied by CG. The inability to identify a small percentage of Ph cells by that method is attributed to sampling error.
One might ask if the difference between 100% Ph' observed by CC and the 90+% observed by HMF in this patient set might be the result of false-negative readings (scoring a Ph' cell as Ph-because of the inability to observe the third signal due to artifact, eg, loss of the Ph chromosome from the spread, overlap of one of the three signals with another, poor staining rendering the smaller Ph' signal invisible in some cells). It is our experience that false-negative cells are not a problem with this procedure. Metaphases analyzed have a recognizable cluster of chromosomal elements mitigating the question of chromosome loss. The dual signals from a chromosome make indistinguishable overlaps unlikely. Even staining and the bright signal seen from the Ph chromosome due to the large size of the probe and hybridization sequences on the chromosomes suggest that the elements being targeted will be visible when present. This position was supported by our observations in the control material where two chromosomal elements were seen in every cell. Therefore, the non-Ph' cells seen in this category of nonresponders were most likely due to the real presence and detection of cells without the translocation in the population. Determining whether they are non-myeloid dividing cells or possible normal myeloid progenitors, and whether there are clinical consequences in patients with different frequencies of them, must await further analyses. Such analyses should be possible now because when samples of 500 cells each from patients differ by as little as 496, the difference is significant at the 99% confidence level.
Among the 10 patients with minor cytogenetic response by CC (Table 3) , highly statistically significant differences in the frequencies in the levels of Ph' cells as determined by CG as opposed to HMF were observed for samples from two patients (D466 and D662j. The HMF results reclassify the patients into the no-response category. Follow-up CG data were available for one of these patients (D466), and it was determined that the cytogenetic response had been lost. This indicated that the HMF result gave a more accurate picture of patient D466's clinical status than the lower Ph+ frequency observed by CG.
Among the patients that were classified as having a partial cytogenetic response by CG, there were two samples (D4 12 and D685) with statistically significant differences in the frequencies of Ph' cells as determined by the two different 100 (14) 100 (20) 100 (20) 100 ( Boldface indicates samples that were reclassified as to cytogenetic * Significantly different from CG result at P i ,001.
t Significantly different from CG result at P i .05.
response as a result of HMF result. NA (2) 0 (500) Abbreviation: NA, not applicable.
methods (Table 3) . Patient D685 was reclassified as a minor responder. The very much higher frequency of Ph+ cells seen in patient D495 using HMF, which also resulted in the patient's reclassification to minor cytogenetic response, lacked statistical significance because of the small number of cells available for CG analysis. Three (patients D032, D135, and D533), or 16%, of the 20 patients classified as having a complete cytogenetic response as determined by finding no Ph+ cells by CG were shown by HMF to have persistent disease ( Table 3 ). All three patients have been recategorized as partial cytogenetic responders. Follow-up data on these patients are not yet available. Once again, the small number of cells analyzed by CG in each of those three cases did not allow us to attach statistical significance to the different outcome achieved by HMF. However, comparison between the patient with the lowest frequency of Ph' cells (yet still greater than 0) as determined by HMF (patient D533) with any other patient showing 0% Ph+ cells by HMF revealed highly statistically significant differences (all with P < .001). While not central to the study, an interesting observation ( Table 3) HMF results in patients with insuflcient metaphases by CG. A proportion of patients receiving alpha interferon or chemotherapy often have insufficient metaphases for analysis by CG. Among all eight patients investigated with insufficient metaphases for CG analysis in our study, all were analyzable by HMF. Four (50%) had 0% Ph' cells by HMF, two had a partial cytogenetic response (6.5% and 9.7% Ph+, respectively), and two had a minor cytogenetic response (46.3% and 39.4% Ph+, respectively) by HMF ( Table 4) .
We conclude that the HMF procedure is a valid method of determining the frequency of Ph+ cells in the bone marrow of patients with CML undergoing therapy. The procedure identifies the frequency of Phi cells at a much higher level of resolution than standard methodology, is often capable of identifying low frequencies of Ph+ cells not identifiably by CC, and can generate such data in samples that are not analyzable by CC.
DISCUSSION
In patients with Ph+ CML, a interferon therapy produces hematologic responses in 70% to 80% and cytogenetic responses in 30% to 50%. Cytogenetic responses are major and durable in 15% to 30% of patients who continue therapy and are associated with significant survival pr~longation.'.~ Thus, monitoring cytogenetic response at frequent intervals is essential for patient care delivery.
Several problems arise in the monitoring of patient response to alpha interferon therapy. The time-consuming CG procedures and the antiproliferative effect of alpha interferon reduce the number of metaphases analyzed to 25 or less; thus, confidence in the measurement is low. For example, in a patient with a complete cytogenetic response (0% Ph+) based on 20-metaphase analysis, the confidence interval in the cytogenetic response is 0% to 11 %. Therefore, many patients may have only a partial cytogenetic response, with the consequent therapeutic and prognostic implications. More significantly, 10% to 20% of samples analyzed on alpha interferon therapy have no metaphases for analysis, requiring interruption of interferon for short periods (3 to 7 days) before CC analysis, repetition of tests, and delays of treatment decisions.
With respect to the assessment of minimal residual disease during therapy, we have shown that complete cytogenetic response by CC may in fact be only a partial cytogenetic response by HMF, or it may be a complete cytogenetic response of high quality (0 Ph+ cells in 500 cells analyzed). This should help in decisions regarding continuation of alpha interferon therapy andor addition of other agents (eg, lowdose cytosine arabinoside [ara-C]), dose schedule adjustment, or even discontinuation of therapy.
HMF addresses these concerns. In this analysis, 24% of patients were reclassified into a cytogenetic response category that is more appropriate than the one assigned by CC (Table 5) . It was also successful in providing response data in patients with insufficient metaphases for regular CC studies. Of significance was the ability of HMF to detect MRD in 3 of 19 patients in complete cytogenetic response by routine CC, thus providing insight into their true response status, which may influence treatment decisions (dose schedule, additional agents, need to continue therapy). Furthermore, in patients shown to be 0% Ph+ by HMF on 500 cells, an argument could be made to reduce or stop a interferon therapy, while continuing close monitoring by HMF. Studies on 500 cells have very narrow confidence intervals ( ? O s % ) and minor changes (less than 4%) observed at periodic intervals (eg, every 3 to 6 months) can be reliable measurements of the efficiency of a particular therapy.
The result finding 5.3% Ph' cells by HMF in the sample from the Ph-patient found to have BCWABL chimeric transcript by RT-PCR is of particular interest. It offers an alternative to the suggestion that subtle or masked translocations, undetectable by CG, may be the basis of such observations.'" Our finding suggests that small proportions of Phi cells, which may not get sampled in the 20 or so cells studied by CG, could provide transcript for such molecular detection. Clearly, more patients with this syndrome need to be studied by HMF before such an explanation for the basis of Ph-, RT-PCR' CML can be generally applied.
From the results reported here, HMF is clearly a highly efficient method for quantitating the level of cancer burden, and possibly also MRD, in hematologic malignancies. While RT-PCR may be more sensitive" than HMF in identifying MRD, it is not enumerative or quantitative and cannot provide information on the constitutive level of Ph' cells, as it depends on the expression of chimeric transcript, levels of which may vary in cells carrying the translocation. However, it should be realized that, unlike RT-PCR, HMF monitors only cycling cells. interphase FISH,'2"4 on the other hand, looks at the constitutive level of cancer cells and does not depend on the cycling status of cells under study. However. substantial levels of false-positive and false-negative readings make quantitative assessment of interphase FISH results difficult. Genomic PCR, which also does not depend on expression of the chimeric locus to be identified, has not yet been shown to be practical in identifying translocations in different patients because of the wide range of positions where translocation breakpoint sites may occur within the large introns that are interrupted by the event. However, new developments in tailoring genomic PCR for individual patients may soon make that technology available to this field,'','' Further work in which these various technologies are performed on the same MRD samples for which HMF has been performed may help define the relevance of data from all these procedures to clinical status and patient outcome.
The major limitation of HMF is the inability of the procedure to detect cytogenetic clonal evolution, an indicator of worse prognosis," as it is focussed on scoring the single cytogenetic event of interest (in this case, the Ph chromosome). For patients with CML undergoing alpha interferon therapy, this limitation may be without serious clinical consequences, as of the 51 CML samples for which CC data were available, none displayed clonal evolution. There is also recent evidence that clonal evolution may not carry the same poor prognostic impact in such cases as when occumng with other features of accelerated phase CML.I8
While HMF can be applied to any hematologic malignancy where the particular nonrandom chromosomal rearrangement in a patient is known and for which appropriate For personal use only. on September 24, 2017. by guest www.bloodjournal.org From FISH probes for its identification have been identified, monitoring for other cytogenetic alterations by CG remains a significant procedure in the management of such disease in patients. CG also has an irreplaceable role in diagnosis where the particular nonrandom chromosomal alteration associated with a patient's disease needs to be initidly identified before any follow-up with HMF can be considered. We conclude, however, that for observing the course of patients having known chromosomal alterations associated with their disease, HMF appears to be most efficient in monitoring the percentage of cells with that alteration in the management of such malignancies. Application of the procedure to other hematologic malignancies where the nature of the chromosomal event associated with the disease has been identified and for which FISH probes are avaialable is in progress.
